Sat, Dec 21, 2024
[Archive]
Volume 31, Issue 147 (July & August 2023)
J Adv Med Biomed Res 2023, 31(147): 358-363 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ahmed Muhmood M, Safi F, Jassam Mohammed A, Saleem Obaid Al-mawla B. Assessment of Interleukin-10, 20, and Matrix Metalloproteinase-7 in Iraqi Patients Infected with COVID-19. J Adv Med Biomed Res 2023; 31 (147) :358-363
URL: http://journal.zums.ac.ir/article-1-7287-en.html
URL: http://journal.zums.ac.ir/article-1-7287-en.html
1- Dept. of Biology, Faculty of Science, The University of Sfax, Sfax, Tunisia , m1988.vip@gmail.com
2- Dept. of Pediatrics, Hedi Chaker Hospital, Faculty of Medicine, The University of Sfax, Sfax, Tunisia
3- Dept of Al-Anbar Health, Ramadi Teaching Hospital for Women and Children, Anbar, Iraq
2- Dept. of Pediatrics, Hedi Chaker Hospital, Faculty of Medicine, The University of Sfax, Sfax, Tunisia
3- Dept of Al-Anbar Health, Ramadi Teaching Hospital for Women and Children, Anbar, Iraq
Abstract: (1135 Views)
Background and Objective: COVID-19, caused by SARS-CoV-2, can lead to a wide range of clinical severities in infected individuals. Among the observed manifestations, pulmonary fibrosis stands out, characterized by chronic inflammation and collagen buildup in the interalveolar space. Numerous studies have indicated that proinflammatory cytokines may contribute to this condition. The cytokine storm, a critical phase in the deterioration of COVID-19 patients, plays a significant role in this process. The main objective of this study was to determine the levels of IL-10, IL-20, and MMP7 in COVID-19-infected people.
Materials and Methods: During the period between November-2022 to March-2023, a case-control study with 200 participants was carried out at Al-Ramadi Hospitals in Anbar province, Iraq. A total of 100 individuals diagnosed with COVID-19 and 100 healthy controls (HCs) took part in the study. Serum concentrations of interleukins, including IL-10, IL-20, and MMP7, were assessed using enzyme-linked immunosorbent assays (ELISA).
Results: The current study revealed significant differences in IL-10 and IL-20 concentrations among the groups being compared with a P-value of <0.01. Notably, the COVID-19 group had significantly more MMP7 than the control group or the group of individuals who had recovered from the disease. This outcome raises the possibility that MMP7 could act as an independent indicator of COVID-19 infection.
Conclusion: Patients with COVID-19 disease had IL-10, IL-20, and MMP-7 levels that were noticeably higher than those found in healthy controls.
Full-Text [PDF 402 kb]
(547 Downloads)
| | Full-Text (HTML) (293 Views)
✅ Patients with COVID-19 disease had IL-10, IL-20, and MMP-7 levels that were noticeably higher than those found in healthy controls.
Type of Study: Original Article |
Subject:
Epidemiologic studies
Received: 2023/07/1 | Accepted: 2023/08/26 | Published: 2023/09/27
Received: 2023/07/1 | Accepted: 2023/08/26 | Published: 2023/09/27
References
1. Al Meani SAL, Abdulkareem AH, Ibrahim MO, Ahmed MM, Mukhlif MY. Assessment the correlation of D-dimer and ferritin level in patients infected with covid-19 in Anbar Governorate of Iraq. Syst Rev Pharm. 2020;11(9):1130-3.
2. Hussein MS, Al Meani SAL, Ahmed MM. Prevalence of COVID-19 pandemic in province of Anbar, Iraq. Nat. Volatiles & Essent. Oils,2021;5292-302.
3. Al Meani SAL, Hamad AA, Abdulkareem AH, Ahmed MM, Salih RM. Assessment of C-reactive protein and lactate dehydrogenase levels in patients infected with COVID-19. Ann Rom Soc Cell Biol. 2021; 1023-7.
4. Al Meani SAL, Ahmed MM, Abdulkareem AH, Hamid NM, Ibrahim MO. Effect of COVID-19 virus on biomass index of infected patients. Syst Rev Pharm. 2020;11(9):1134-6.
5. Hussein MS, Al-Qaysi A-MK, Meani SAL Al, Ahmed MM, Abed NS, Ibrahim MO. Assessment of Cinamic acid and Costus roots extract against MDR-K. pneumoniae isolated from patients of COVID-19. Res J Pharm Technol. 2022;15(12):5724-8. [DOI:10.52711/0974-360X.2022.00965]
6. Rabaan AA, Al-Ahmed SH, Muhammad J, Khan A, Sule AA, Tirupathi R, et al. Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines. 2021;9(5):436. [DOI:10.3390/vaccines9050436] [PMID] [PMCID]
7. Dhar SK, Vishnupriyan K, Damodar S, Gujar S, Das M. IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. Heliyon. 2021;7(2):e06155. [DOI:10.1016/j.heliyon.2021.e06155] [PMID] [PMCID]
8. Lu L, Zhang H, Dauphars DJ, He YW. A potential role of interleukin 10 in COVID-19 pathogenesis. Trends Immunol. 2021;42(1):3-5. [DOI:10.1016/j.it.2020.10.012] [PMID] [PMCID]
9. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007;178(4):2229-40. [DOI:10.4049/jimmunol.178.4.2229] [PMID]
10. Tomlin H, Piccinini AM. A complex interplay between the extracellular matrix and the innate immune response to microbial pathogens. Immunology. 2018;155(2):186-201. [DOI:10.1111/imm.12972] [PMID] [PMCID]
11. Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuna JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21(24):9739. [DOI:10.3390/ijms21249739] [PMID] [PMCID]
12. Zanza C, Romenskaya T, Manetti AC, Franceschi F, La Russa R, Bertozzi G, et al. Cytokine storm in COVID-19: immunopathogenesis and therapy. Medicina (B Aires). 2022;58(2):144. [DOI:10.3390/medicina58020144] [PMID] [PMCID]
13. Al Omari O, Al Sabei S, Al Rawajfah O, Abu Sharour L, Aljohani K, Alomari K, et al. Prevalence and predictors of depression, anxiety, and stress among youth at the time of COVID-19: an online cross-sectional multicountry study. Depress Res Treat. 2020; 2020. [DOI:10.1155/2020/8887727] [PMID] [PMCID]
14. Alsofayan YM, Althunayyan SM, Khan AA, Hakawi AM, Assiri AM. Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study. J Infect Public Health. 2020; 13(7):920-5. [DOI:10.1016/j.jiph.2020.05.026] [PMID] [PMCID]
15. Barry P. Beginning theory: An introduction to literary and cultural theory. In: Beginning theory (fourth edition). Manchester university press; 2020. [DOI:10.7765/9781526153524]
16. Alamri F, Alsofayan Y, AlRuthia Y, Alahmari A, Almuzaini Y, Abo Gazalah F, et al. Predictors of hospitalization among older adults with COVID-19 in Saudi Arabia: a cross-sectional study of a nationally representative sample. Risk Manag Health Policy. 2021;875-86. [DOI:10.2147/RMHP.S294786] [PMID] [PMCID]
17. Shahriarirad R, Khodamoradi Z, Erfani A, Hosseinpour H, Ranjbar K, Emami Y, et al. Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. BMC Infect Dis. 2020; 20:1-12. [DOI:10.1186/s12879-020-05128-x] [PMID] [PMCID]
18. Islam H, Chamberlain TC, Mui AL, Little JP. Elevated interleukin-10 levels in COVID-19: potentiation of pro-inflammatory responses or impaired anti-inflammatory action? Front Immunol. 2021;12: 677008. [DOI:10.3389/fimmu.2021.677008] [PMID] [PMCID]
19. Chang Y, Bai M, You Q. Associations between serum interleukins (IL-1β, IL-2, IL-4, IL-6, IL-8, and IL-10) and disease severity of COVID-19: A systematic review and meta-analysis. Biomed Res Int. 2022; 2022. [DOI:10.1155/2022/2755246] [PMID] [PMCID]
20. Najafi-Fard S, Petruccioli E, Farroni C, Petrone L, Vanini V, Cuzzi G, et al. Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy. Frontiers in immunology.2022; 13:984098 [DOI:10.3389/fimmu.2022.984098] [PMID] [PMCID]
21. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020; 9(1):1123-30. [DOI:10.1080/22221751.2020.1770129] [PMID] [PMCID]
22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5] [PMID]
23. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate forms of Coronavirus Disease. J Clin Invest. 2019; 82:137244.
24. Assaid N, Sarih M. COVID-19: The immune responses and immunotherapy. Moroccan J Public Health. 2020; 1(1):71-84.
25. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020; 9 (1): 1123-30. [DOI:10.1080/22221751.2020.1770129] [PMID] [PMCID]
26. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;827. [DOI:10.1101/2020.02.18.20024364]
27. Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J, et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI insight. 2020;5(13). [DOI:10.1172/jci.insight.139834] [PMID] [PMCID]
28. Siouda M, Dujardin AD, Barbollat-Boutrand L, Mendoza-Parra MA, Gibert B, Ouzounova M, et al. CDYL2 epigenetically regulates MIR124 to control NF-κB/STAT3-dependent breast cancer cell plasticity. Iscience. 2020;23(6):101141. [DOI:10.1016/j.isci.2020.101141] [PMID] [PMCID]
29. Saheb Sharif-Askari F, Saheb Sharif-Askari N, Hafezi S, Goel S, Ali Hussain Alsayed H, Ansari AW, et al. Upregulation of interleukin-19 in saliva of patients with COVID-19. Sci Rep. 2022;12(1):16019. [DOI:10.1038/s41598-022-20087-w] [PMID] [PMCID]
30. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19(1):683-765. [DOI:10.1146/annurev.immunol.19.1.683] [PMID]
31. Saraiva M, Vieira P, O'garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2019;217(1):e20190418. [DOI:10.1084/jem.20190418] [PMID] [PMCID]
32. Chan CS, Ming-Lum A, Golds GB, Lee SJ, Anderson RJ, Mui AL-F. Interleukin-10 inhibits lipopolysaccharide-induced tumor necrosis factor-α translation through a SHIP1-dependent pathway. J Biol Chem. 2012;287(45):38020-7. [DOI:10.1074/jbc.M112.348599] [PMID] [PMCID]
33. Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res. 2016;17:1-10. [DOI:10.1186/s12931-016-0343-6] [PMID] [PMCID]
34. Chavez-Galan L, Ruiz A, Martinez-Espinosa K, Aguilar-Duran H, Torres M, Falfan-Valencia R, et al. Circulating levels of PD-L1, TIM-3 and MMP-7 are promising biomarkers to differentiate COVID-19 patients that require invasive mechanical ventilation. Biomolecules. 2022;12(3):445. [DOI:10.3390/biom12030445] [PMID] [PMCID]
35. Burke B. The role of matrix metalloproteinase 7 in innate immunity. Immunobiology. 2004;209(1-2):51-6. [DOI:10.1016/j.imbio.2004.04.005] [PMID]
36. Alkanlı N, Ay A. Matrix metalloproteinase gene variations and expression levels in breast cancer development. GEVHER NESIBE J Med Heal Sci. 2022;7(16):82-91. [DOI:10.46648/gnj.322]
37. Davey A, McAuley DF, O'Kane CM. Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. Eur Respir J. 2011;38(4):959-70. [DOI:10.1183/09031936.00032111] [PMID]
38. Buendía-Roldán I, Fernandez R, Mejía M, Juarez F, Ramirez-Martinez G, Montes E, et al. Risk factors associated with the development of interstitial lung abnormalities. Eur Respir J. 2021;58(2). [DOI:10.1183/13993003.03005-2020] [PMID]
39. da Silva-Neto PV, do Valle VB, Fuzo CA, Fernandes TM, Toro DM, Fraga-Silva TF, et al. Matrix metalloproteinases on severe COVID-19 lung disease pathogenesis: cooperative actions of MMP-8/MMP-2 axis on immune response through HLA-G shedding and oxidative stress. Biomolecules. 2022;12(5):604. [DOI:10.3390/biom12050604] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
